Abstract:Melanoma is the most fatal skin cancer. In the early stages, it can be safely treated with surgery alone. However, since 2011, there has been an important revolution in the treatment of melanoma with new effective treatments. Targeted therapy and immunotherapy with checkpoint inhibitors have changed the history of this disease. To date, more than half of advanced melanoma patients are alive at 5 years; despite this breakthrough, approximately half of the patients still do not respond to treatment. For these reasons, new therapeutic strategies are required to expand the number of patients who can benefit from immunotherapy or combination with targeted therapy. Current research aims at preventing primary and acquired resistance, which are both responsible for treatment failure in about 50% of patients. This could increase the effectiveness of available drugs and allow for the evaluation of new combinations and new targets. The main pathways and molecules under study are the IDO inhibitor, TLR9 agonist, STING, LAG-3, TIM-3, HDAC inhibitors, pegylated IL-2 (NKTR-214), GITR, and adenosine pathway inhibitors, among others (there are currently about 3000 trials that are evaluating immunotherapeutic combinations in different tumors). Other promising strategies are cancer vaccines and oncolytic viruses. Another approach is to isolate and remove immune cells (DCs, T cells, and NK cells) from the patient's blood or tumor infiltrates, add specific gene fragments, expand them in culture with growth factors, and re-inoculate into the same patient. TILs, TCR gene transfer, and CAR-T therapy follow this approach. In this article, we give an overview over the current status of melanoma therapies, the clinical rationale for choosing treatments, and the new immunotherapy approaches.

Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma

The current progress of PD-1 / PD-L1 mAb applications in melanoma immunotherapy

Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential

Immunotherapy for Skin Cancer

Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities

Interaction of Molecular Alterations with Immune Response in Melanoma

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

Applications of Melanin and Melanin-Like Nanoparticles in Cancer Therapy: A Review of Recent Advances

Research Progress of PD-1/PD-L1 Checkpoint Inhibitors in (neo) Adjuvant Therapy for Malignant Melanoma

PD-1 blockade treatment in melanoma: Mechanism of response and tumor-intrinsic resistance

Epidrugs in the Immunotherapy of Cutaneous and Uveal Melanoma

Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma

Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy

A Review of Advanced Cutaneous Melanoma Therapies and Their Mechanisms, from Immunotherapies to Lysine Histone Methyl Transferase Inhibitors

Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy

Immunotherapy of Melanoma: a Critical Review of Current Concepts and Future Strategies

Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma

Advances in immunotherapy for mucosal melanoma: harnessing immune checkpoint inhibitors for improved treatment outcomes

The safety of anti PD-1 therapeutics for the treatment of melanoma

Current understanding of epigenetics role in melanoma treatment and resistance

Immunotherapy of Human Melanoma: Past, Present, Future